Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

927
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
927
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

752
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
752
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.5K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.4K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.6K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A proteome-wide atlas of humoral immunity to <i>Mycobacterium tuberculosis</i> across the spectrum of disease.

Frontiers in immunology·2026
Same author

Deep learning approach for probabilistic pulmonary function estimation from chest X-ray and peak expiratory flow rate.

Communications medicine·2026
Same author

Interventions to reduce the impact of post-tuberculosis lung disease: a scoping review of the literature.

BMC pulmonary medicine·2026
Same author

Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models.

Research square·2026
Same author

Statins for polycystic ovary syndrome in varying resource settings: a phenome-wide association study and evidence synthesis.

Frontiers in pharmacology·2025
Same author

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.

The Lancet. Infectious diseases·2025
Same journal

A guide to CAR T cell therapies: development, current status and future prospects.

Nature reviews. Immunology·2026
Same journal

Macrophages in embryonic development.

Nature reviews. Immunology·2026
Same journal

Glycolytic capacity instructs tumour vasculature and response to immunotherapy.

Nature reviews. Immunology·2026
Same journal

Vaginal NK cells limit epithelial barrier disruption during infection.

Nature reviews. Immunology·2026
Same journal

New insights into progenitor exhausted T cell populations.

Nature reviews. Immunology·2026
Same journal

T cell engagers in autoimmune diseases.

Nature reviews. Immunology·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Advancing host-directed therapy for tuberculosis.

Robert S Wallis1, Richard Hafner2

  • 1Aurum Institute, Johannesburg 2193, South Africa.

Nature Reviews. Immunology
|March 14, 2015
PubMed
Summary
This summary is machine-generated.

New host-directed therapies offer hope for treating Mycobacterium tuberculosis infections. These treatments may shorten tuberculosis duration, prevent drug resistance, and reduce lung damage by enhancing the body's immune response.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.8K

Related Experiment Videos

Last Updated: Apr 16, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.8K

Area of Science:

  • Infectious diseases
  • Immunology
  • Pharmacology

Background:

  • Tuberculosis (TB) remains a significant global health challenge requiring improved treatment strategies.
  • Current TB treatments can be lengthy and face challenges with drug resistance and lung injury.
  • Host-directed therapies (HDTs) offer a novel approach to combat Mycobacterium tuberculosis infection.

Purpose of the Study:

  • To discuss the potential of adjunctive host-directed therapies in improving tuberculosis treatment outcomes.
  • To explore how HDTs can shorten treatment duration, prevent resistance, and mitigate lung damage.
  • To highlight promising candidates for HDTs currently in or ready for clinical trials.

Main Methods:

  • Review of existing literature on host-directed therapies for tuberculosis.
  • Analysis of mechanisms by which HDTs modulate host immune responses against Mycobacterium tuberculosis.
  • Identification of potential HDT candidates, including repurposed drugs, for clinical evaluation.

Main Results:

  • HDTs can enhance macrophage effector functions, including autophagy and antimicrobial peptide production.
  • HDTs may reduce lung inflammation and matrix destruction associated with tuberculosis.
  • Several promising HDT candidates are available for Phase II clinical trials.

Conclusions:

  • Adjunctive host-directed therapies hold significant promise for accelerating tuberculosis treatment response.
  • HDTs have the potential to improve overall tuberculosis treatment outcomes and reduce disease-associated complications.
  • Further clinical evaluation of HDTs is warranted to combat Mycobacterium tuberculosis infection effectively.